Cited by 84Psychedelics and Drug StudiesTreatment of Major DepressionPsychotherapy Techniques and Applications

Psychedelics therapeutics: What we know, what we think, and what we need to research

Open access
Nutt, David, Spriggs, Meg, Erritzoe, David·2023·Neuropharmacology

Abstract

Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge. In this commentary we lay out the knowledge framework that should be taken into account by all innovative researchers in this field.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2022.109257

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Psychedelic-assisted psychotherapy is demonstrating promising outcomes in treating a wide range of mental health issues, suggesting its efficacy may be transdiagnostic.

    “PAP is demonstrating promising outcomes in treating a wide range of mental health issues, ranging from depression to post-traumatic stress disorder, suggesting this efficacy may be transdiagnostic (20, 21).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nutt, D., Spriggs, M., & Erritzoe, D.
Affiliations
Imperial College London (GB)
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2023-02
Volume
223
Pages
109257
ISSN
0028-3908 (ISSN-L)
OpenAlex
W4297373842
Cited by
84
References
32
Citations by year
2026: 11 · 2025: 11 · 2024: 42 · 2023: 19 · 2022: 1
FWCI
3.04
Type
journal article
Language
en
Open access
Locations
  • Neuropharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institute for Health and Care Research (ACF-2013-21-501, CL-2017-21-004)
  • Academy of Medical Sciences (SGL019\1063)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
psychedelics, psychedelic therapy, psychiatric treatment, psychiatric diagnosis, knowledge framework, research priorities
MeSH terms
Hallucinogens, Psychiatry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review